• AZ Connect
• AZ Gateway
• For Patients
• Log In

Home

*Based on the percent of covered lives with access at Tier 1 or Tier 2 status, measured monthly from June 2006 through May 2010. "Covered lives" includes commercial, Medicare, and Medicaid coverage. Formulary coverage will vary by health plan. Preferred coverage is based on data showing coverage of NEXIUM at Tier 1 or Tier 2, and may include prior authorization, quantity limits, step therapy, and other restrictions.

^†Source: Fingertip Formulary^® database (accessed May 26, 2010). The formulary information reported by Fingertip Formulary covers 95% of the covered lives in the US.

Important Safety Information

• NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
• Symptomatic response to therapy does not rule out the presence of gastric malignancy
• Atrophic gastritis has occasionally been noted with long-term therapy with omeprazole
• Long-term and multiple daily dose proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine
• Hypomagnesemia has been reported rarely with prolonged treatment with PPI therapy and may require discontinuing PPI therapy
• Concomitant use of NEXIUM and St. John's wort or rifampin can substantially decrease NEXIUM concentrations. Avoid concomitant use
• Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended. NEXIUM may increase the plasma levels of saquinavir. Dose reduction of saquinavir should be considered
• Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs for which gastric pH affects bioavailability (eg, ketoconazole, iron salts, and digoxin)
• NEXIUM may increase systemic exposure of cilostazol and one of its active metabolites. Consider dose reduction
• NEXIUM I.V. should be used only when oral therapy with NEXIUM is not possible or appropriate
• In adults, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, and abdominal pain
• The ARs reported at a frequency of 1% or greater with NEXIUM I.V. in clinical trials were headache, flatulence, nausea, abdominal pain, injection site reaction, diarrhea, dry mouth, dizziness/vertigo, constipation, and pruritus
• In pediatric patients 1 to 17 years of age, the most frequently reported ARs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence

Please see the full Prescribing Information available at www.NexiumTouchPoints.com

NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.

Please click here for the full Prescribing Information (PDF – 303 KB) for NEXIUM.

Please click here for the full Prescribing Information (PDF - 72 KB) for NEXIUM I.V.

NEXIUM and the color purple as applied to the capsule are registered trademarks and Circle T and Purple Plus are trademarks of the AstraZeneca group of companies.

This product information is intended for US Health Care professionals only.

©2011 AstraZeneca. All rights reserved. 1291400 9/11